Gliknik invests a significant percentage of its expenses into development of its intellectual property portfolio. For about a decade, Gliknik has been represented by Cooley LLP on intellectual property matters.

In our latest complete year Gliknik had 13 patents issued in 11 countries across 5 patent families.

Gliknik patent filings are worldwide. These are issued US patents that are either owned by or licensed by Gliknik:

U.S. Patent No. 11331372
“Methods of treating inflammatory disorders with multivalent Fc compounds”

U.S. Patent No. 11155574
“Manufacturing optimization of GL-2045, a multimerizing stradomer”

U.S. Patent No. 11117940
“Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions”

U.S. Patent No. 11034775
“Cysteine-optimized stradomers”

U.S. Patent No. 10941191
“Immunoglobulin constant region Fc receptor binding agents”

U.S. Patent No. 10851154
“Immunoglobulin constant region Fc receptor binding agents”

U.S. Patent No. 10208105
“Immunoglobulin constant region Fc receptor binding agents”

U.S. Patent No. 9926362
“Immunoglobulin constant region Fc receptor binding agents”

U.S. Patent No. 9683044
“Molecules with antigen binding & polyvalent Fcgamma receptor binding activity”

U.S. Patent No. 9512208
“Immunoglobulin constant region FC receptor binding agents”

U.S. Patent No. 9512210
“Immunoglobulin constant region Fc receptor binding agents”

U.S. Patent No. 20150056185
“Immunoglobulin constant region Fc receptor binding agents”

U.S. Patent No. 20140370012
”Fusion proteins comprising IgG2 hinge domains”

U.S. Patent No. 20140105913
“Immunoglobulin constant region Fc receptor binding agents”

U.S. Patent No. 8,680,237
“Immunoglobulin constant region FC receptor binding agents”

U.S. Patent No. 20140072582
“Immunoglobulin constant region FC receptor binding agents”

U.S. Patent No. 20120309941
“Immunoglobulin constant region FC receptor binding agents”

U.S. Patent No. 20120121578
”Methods of using immunoglobulin aggregates”